- Open
- 13284.00
- High
- 13396.00
- Low
- 13156.00
- Close
- 13218.00
- Change
- +62.00 (0.47%)
- Volume
- 1,578,491
⌘K
| 15 Jun 2026 | 07:00:09 | Truqap approved in US for prostate cancer |
| 1 Jun 2026 | 15:05:01 | Admission of Further Securities to Trading |
| 1 Jun 2026 | 15:00:00 | Total Voting Rights |
| 29 May 2026 | 07:00:05 | Imfinzi approved in US for early bladder cancer |
| 27 May 2026 | 07:00:06 | US FDA decision date on camizestrant extended |
| 24 Feb 2026 | 2025 Annul Report & 20-F Information | |
| 18 Feb 2025 | 2024 Annual Report & 20-F Information | |
| 20 Feb 2024 | AstraZeneca PLC Annual Report & 20-F Information 2023 |
We are a multinational pharmaceutical corporation with a significant presence in the United Kingdom. Our mission is to advance scientific frontiers and provide transformative medications that improve lives.
Lord Goldsmith and 5 other people have interests in this issuer
| 15 Jun 2026 | 07:00:09 | Truqap approved in US for prostate cancer |
| 1 Jun 2026 | 15:05:01 | Admission of Further Securities to Trading |
| 1 Jun 2026 | 15:00:00 | Total Voting Rights |
| 29 May 2026 | 07:00:05 | Imfinzi approved in US for early bladder cancer |
| 27 May 2026 | 07:00:06 | US FDA decision date on camizestrant extended |
| 24 Feb 2026 | 2025 Annul Report & 20-F Information | |
| 18 Feb 2025 | 2024 Annual Report & 20-F Information | |
| 20 Feb 2024 | AstraZeneca PLC Annual Report & 20-F Information 2023 |
We are a multinational pharmaceutical corporation with a significant presence in the United Kingdom. Our mission is to advance scientific frontiers and provide transformative medications that improve lives.
Lord Goldsmith and 5 other people have interests in this issuer